Jump to content

GUD.V - Knight Therapeutics


bz1516

Recommended Posts

  • 1 month later...
  • Replies 212
  • Created
  • Last Reply

Top Posters In This Topic

  • 2 weeks later...

 

This presentation is from last February.  I'm confused why you're posting it today?

 

 

 

It is a new version to me, only available on the French website. The previous one (and current on the English side) was August.

 

Yes but this one is from February 2020.

Link to comment
Share on other sites

 

This presentation is from last February.  I'm confused why you're posting it today?

 

 

 

It is a new version to me, only available on the French website. The previous one (and current on the English side) was August.

 

Yes but this one is from February 2020.

 

You are right, I have removed my previous messages. My bad. That said it is amazing they haven’t got new deals from LATAM since last year.

Link to comment
Share on other sites

 

You are right, I have removed my previous messages. My bad. That said it is amazing they haven’t got new deals from LATAM since last year.

 

Agreed!  I assume from the shelf prospectus that they have some consolidation opportunities in mind, and I like that they were repurchasing lots of shares in February, but the apparent lack of progress in LATAM is discomforting. Looking forward to a status update when they report Q4.

Link to comment
Share on other sites

  • 2 weeks later...

[quote]Jonathan Goodman[/b>


It's Jonathan speaking. As you know, that I am frugal, some say, cheap. And we have purchased -- in 2021, we have purchased year-to-date 2.9 million shares at $5.25 a share. And I'll just leave it at that. Thank you for your confidence in the Knight team and joining our Q4 2020 conference call. Please stay healthy and stay safe.


Haha, that's one way to end an earnings call!

Link to comment
Share on other sites

"The bullish bet here is that patience will pay off, just as it did when Mr. Goodman led Paladin. Under his leadership, Paladin’s share price rose from its initial public offering of $1.50 in 1995 to a high of $151 before the company’s sale to Endo International PLC in 2014."

Knight Therapeutics stock underperforms, disappoints faithful - The Globe and Mail

We are almost there, 6 years done, 13 years to go.

 

Link to comment
Share on other sites

  • 4 weeks later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now



×
  • Create New...